Meniere's Disease
31
4
5
17
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
12 trials with published results (39%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
19.4%
6 terminated out of 31 trials
73.9%
-12.6% vs benchmark
39%
12 trials in Phase 3/4
71%
12 of 17 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 17 completed trials
Clinical Trials (31)
CAVA: Dizziness Trial
SPI-1005 for the Treatment of Meniere's Disease (Open Label)
Deep Phenotyping of Hearing Instability Disorders: Cohort Establishment, Biomarker Identification, Development of Novel Phenotyping Measures, and Discovery of Therapeutic Targets
Study to Evaluate SPI-1005 in Adults With Meniere's Disease
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
Genetic and Biohumoral Factors Involved in Menière's Disease and Their Correlation With Phenotypes
Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease
Modulating Auditory Symptoms and Vertigo of Meniere's Disease by Non-invasive Mastoid Electric Stimulation
SPI-1005 for the Treatment of Patients With Meniere's Disease
A 6-Month Extension Study of OTO-104 in Meniere's Disease
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
Study of OTO-104 in Subjects With Unilateral Meniere's Disease
A 6-Month Extension Study of OTO-104 in Meniere's Disease
Study of Lamotrigine to Treat Ménière's Disease
Famvir for Treatment of Hearing in Unilateral Meniere's Disease
Sildenafil For Meniere's Disease
Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease
Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease
Cochlear Implantation After Labyrinthectomy or a Translabyrinthine Surgical Approach
Open Label Study of OTO-104 in Subjects With Meniere's Disease